Investor Area

Home / Investor Area / Nomura Update “Considerable upside should NSV trials be successful”

Nomura Update “Considerable upside should NSV trials be successful”

NSV is a de-pigmenting disease that affects c10mn persons in the US and EU. CUV’s afamelanotide is being evaluated as a combination therapy with narrowband UVB light therapy in two clinical studies in patients with NSV. In early Phase II trial results presented at a recent conference, the NB-UVB plus afamelanotide group showed earlier onset of repigmentation compared to controls.